Over the last several years, new generation vaccine systems that are based on proteins, peptides, or DNA have shown great promise compared to the traditional vaccines based on inactivated or attenuated whole organisms. However, due to the lower efficiencies and higher cost of these new generation vaccines, they are seldom used alone. Rather, their formulations often contain adjuvants, either to enhance the immune responses or to reduce the effective dose. The present article will provide a brief overview of recent advances in peptide‐ or protein-based cancer vaccine adjuvants, focusing mainly on Liposome‐Protamine‐DNA (LPD) nanoparticle‐mediated antigen delivery. The molecular basis and signaling pathways leading to the activation and maturation of antigen presenting cells (APC) by adjuvants are discussed. Another consideration of the liposome‐based vaccine delivery system is the antigen targeting. Therefore, the second part of this review will discuss the strategies used for targeted delivery of antigen, from the organ level to the cellular, the sub‐cellular, and the molecular level.
Recent Advances in Liposome‐Based Nanoparticles for Antigen Delivery
Log in via your institution
Log in to Taylor & Francis Online
Restore content access
Restore content access for purchases made as guestPDF download + Online access
- 48 hours access to article PDF & online version
- Article PDF can be downloaded
- Article PDF can be printed
Issue Purchase
- 30 days online access to complete issue
- Article PDFs can be downloaded
- Article PDFs can be printed
Related Research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.